Vertex Pharmaceuticals (VRTX) Aktievy
Vertex Pharmaceuticals Incorporated är ett bioteknikföretag verksamt i USA, Europa och internationellt. Mer information
| Snöflinga Score | |
|---|---|
| Värdering | 3/6 |
| Framtida tillväxt | 2/6 |
| Tidigare resultat | 5/6 |
| Finansiell hälsa | 6/6 |
| Utdelningar | 0/6 |
Belöningar
Riskanalys
Inga risker upptäckta för VRTX från våra riskkontroller.
VRTX Community Fair Values
Create NarrativeSee what 252 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Vertex Pharmaceuticals Incorporated Konkurrenter
Prishistorik och prestanda
| Historiska aktiekurser | |
|---|---|
| Aktuell aktiekurs | US$525.73 |
| 52 veckors högsta | US$546.17 |
| 52 veckors lägsta | US$374.17 |
| Beta | 0.30 |
| 1 månads förändring | 9.47% |
| 3 månaders förändring | 16.72% |
| 1 års förändring | 32.79% |
| 3 års förändring | 53.09% |
| 5 års förändring | 169.92% |
| Förändring sedan börsintroduktionen | 11,582.89% |
Senaste nyheter och uppdateringar
Uppdatering av berättelse • Aug 04
VRTX: Endocrinology Expansion And Nephrology Pipeline Will Drive Next Phase
Analysts have nudged their price targets on Vertex Pharmaceuticals higher, generally into a $550 to $605 range, citing raised FY26 revenue guidance, steady cystic fibrosis performance, and a growing set of potential catalysts across hematology, nephrology, pain, and the newly added endocrinology portfolio. Analyst Commentary Street research on Vertex Pharmaceuticals points to a generally constructive tone, with multiple firms lifting price targets and focusing on execution around the cystic fibrosis franchise, the expanding pipeline and the new endocrinology pillar from the Crinetics deal.Seeking Alpha • Aug 04
Vertex Pharmaceuticals: A Transition Year Into A Multi-Franchise Growth Story
Summary Vertex Pharmaceuticals is executing a pivotal transition year, evolving from a CF-dominated biotech to a multi-franchise growth platform. 2Q26 revenue rose 12% to $3.33 billion, with strong CF performance and early scaling of Casgevy and Journvax supporting raised FY26 guidance to $13.1–$13.2 billion. VRTX is aggressively reinvesting in pipeline and commercial launches, leveraging a $13.6 billion cash position and diversifying with the Crinetics acquisition. Valuation reflects CF durability and early multi-franchise success, but longer-term optionality in type 1 diabetes and pipeline breakthroughs is not fully priced in. Read the full article on Seeking AlphaRecent updates
Uppdatering av berättelse • Aug 04
VRTX: Endocrinology Expansion And Nephrology Pipeline Will Drive Next Phase
Analysts have nudged their price targets on Vertex Pharmaceuticals higher, generally into a $550 to $605 range, citing raised FY26 revenue guidance, steady cystic fibrosis performance, and a growing set of potential catalysts across hematology, nephrology, pain, and the newly added endocrinology portfolio. Analyst Commentary Street research on Vertex Pharmaceuticals points to a generally constructive tone, with multiple firms lifting price targets and focusing on execution around the cystic fibrosis franchise, the expanding pipeline and the new endocrinology pillar from the Crinetics deal.Seeking Alpha • Aug 04
Vertex Pharmaceuticals: A Transition Year Into A Multi-Franchise Growth Story
Summary Vertex Pharmaceuticals is executing a pivotal transition year, evolving from a CF-dominated biotech to a multi-franchise growth platform. 2Q26 revenue rose 12% to $3.33 billion, with strong CF performance and early scaling of Casgevy and Journvax supporting raised FY26 guidance to $13.1–$13.2 billion. VRTX is aggressively reinvesting in pipeline and commercial launches, leveraging a $13.6 billion cash position and diversifying with the Crinetics acquisition. Valuation reflects CF durability and early multi-franchise success, but longer-term optionality in type 1 diabetes and pipeline breakthroughs is not fully priced in. Read the full article on Seeking Alpha
Uppdatering av berättelse • Jul 08
VRTX: Rich Crinetics Deal Will Weigh On Future Risk Reward Profile
Vertex Pharmaceuticals' fair value estimate has been adjusted higher by about $9.69 to $423.75 as analysts factor in updated assumptions on revenue growth, margins, and future P/E following the Crinetics acquisition and a series of upward price target revisions, including recent moves to $570 at RBC Capital and $350 at Baird. Analyst Commentary Recent research on Vertex Pharmaceuticals clusters around the planned Crinetics acquisition and how it reshapes the company’s pipeline mix, capital deployment, and earnings profile.
Uppdatering av berättelse • Jun 17
VRTX: Kidney Franchise And Pipeline Expansion Will Drive Future Stock Upside
Vertex Pharmaceuticals' latest narrative update reflects a modest recalibration in analyst price targets, with figures such as Truist's move to $542 and Wells Fargo's lift to $550 framed around analysts' view that the emerging kidney franchise can grow into blockbuster assets and broaden the company's portfolio. Analyst Commentary Recent Street research on Vertex Pharmaceuticals highlights a generally constructive tone, with bullish analysts pointing to the expanding kidney franchise and a series of upward price target revisions as key supports for the stock's valuation and growth narrative.Uppdatering av berättelse • Jun 03
VRTX: Kidney Franchise Progress Will Drive Future Upside Beyond CF
Analysts have nudged their average price target on Vertex Pharmaceuticals higher by a few dollars to around the mid $500s to low $600s, citing positive Phase 3 RAINIER data and the perceived de-risking of the emerging kidney franchise as key reasons for the change. Analyst Commentary Bullish analysts are broadly aligning around a more constructive view on Vertex Pharmaceuticals following the RAINIER readout, with several pointing to the kidney franchise as a key driver for the stock story alongside the established cystic fibrosis business.Uppdatering av berättelse • May 19
VRTX: CF Franchise And Nephrology Pipeline Will Shape Balanced Future Risk Profile
Analysts have inched their fair value target for Vertex Pharmaceuticals higher to about $414 per share. This reflects updated assumptions that pair slightly more conservative revenue growth expectations with higher projected profit margins and a lower anticipated future P/E multiple.Uppdatering av berättelse • May 05
VRTX: CF Base And Nephrology Expansion Will Define Balanced Future Risk Profile
Analysts have inched their average price target for Vertex Pharmaceuticals higher by a few dollars, citing stronger confidence in povetacicept after positive Phase 3 RAINIER data in IgA nephropathy and a broader nephrology pipeline thesis, while keeping valuation assumptions such as P/E and discount rate broadly consistent. Analyst Commentary Recent Street research on Vertex Pharmaceuticals has centered on povetacicept and the nephrology pipeline, with several major firms adjusting their models after the Phase 3 RAINIER interim readout in IgA nephropathy and following Q4 results.Uppdatering av berättelse • Apr 20
VRTX: CF Franchise And Kidney Pipeline Will Shape Balanced Risk Profile
Vertex Pharmaceuticals' fair value estimate has shifted from $403.80 to $412.49 as analysts refresh models following multiple price target increases tied to positive Phase 3 povetacicept data and a reassessment of the company's nephrology pipeline potential. Analyst Commentary Recent Street research on Vertex Pharmaceuticals has leaned constructive overall, with several firms lifting price targets following the Phase 3 RAINIER interim readout for povetacicept and updating models around the nephrology pipeline.Uppdatering av berättelse • Apr 05
VRTX: Renal Franchise Progress And CF Leadership Will Drive Future Upside
Vertex Pharmaceuticals' analyst fair value estimate has shifted to $641 from $604. This reflects analysts' updated views on the company's diversified pipeline following positive Phase 3 povetacicept data in IgA nephropathy and a series of higher Street price targets.Uppdatering av berättelse • Mar 22
VRTX: Renal Trial Success And Nephrology Pipeline Will Drive Next Phase
Vertex Pharmaceuticals' analyst fair value estimate has moved from $504.04 to $547.72. Analysts point to higher modeled revenue growth, slightly stronger profit margins, a richer future P/E assumption, and a wave of Street price target hikes tied to positive povetacicept Phase 3 RAINIER data and the growing nephrology pipeline.Uppdatering av berättelse • Mar 06
VRTX: CF Dependence Will Heighten Risk Around Upcoming Renal Readouts
Analysts have nudged their target on Vertex Pharmaceuticals higher, with our fair value estimate moving from $401.30 to $403.80. This reflects updated Q4 results, slightly adjusted revenue growth and margin assumptions, and ongoing confidence in the broader pipeline, as seen in a series of recent price target increases across the Street.Uppdatering av berättelse • Feb 20
VRTX: CF Reliance Will Expose Renal Pipeline Execution Risks
Vertex Pharmaceuticals' updated analyst price target reflects an increase of $23.78 to $401.30, as analysts incorporate refreshed Q4 outcomes, pipeline commentary on programs like povetacicept and IgAN, and modest adjustments to assumptions for revenue growth, profit margin, and future P/E. Analyst Commentary Street research around Vertex Pharmaceuticals has been active following the latest Q4 update, with several firms revisiting their models, refreshing pipeline assumptions, and revising price targets.Uppdatering av berättelse • Feb 06
VRTX: CF Dependence And Pipeline Execution Risks Will Test Bullish Repricing
Analysts have raised their fair value estimate for Vertex Pharmaceuticals by about US$33 to approximately US$378, citing a series of recent rating upgrades and higher price targets linked to its cystic fibrosis franchise and late-stage pipeline potential. Analyst Commentary Recent research on Vertex Pharmaceuticals has been dominated by upgrades and higher price targets, with several firms shifting to more positive ratings and highlighting the cystic fibrosis portfolio and late stage pipeline as key supports for the updated fair value assessments.Uppdatering av berättelse • Jan 23
VRTX: CF Cash Flows And Renal Data Will Shape Balanced Next Phase
Analysts have nudged their fair value estimate for Vertex Pharmaceuticals higher to about $504, citing a slightly richer assumed future P/E multiple and modestly stronger revenue growth expectations, even as they factor in a lower profit margin and a slightly higher discount rate. Analyst Commentary Recent Street research on Vertex Pharmaceuticals has turned more constructive, with several firms shifting to more positive ratings and setting price targets above the current fair value estimate.Uppdatering av berättelse • Jan 09
VRTX: CF Durability And Kidney Pipeline Data Will Define Next Phase
Analysts have lifted their Vertex Pharmaceuticals fair value estimate by about US$11 to US$496.16, reflecting updated assumptions on revenue growth, margins and future P/E, as recent research highlights confidence in the durability of its cystic fibrosis franchise and potential upside from its broader pipeline. Analyst Commentary Recent Street research around Vertex Pharmaceuticals points to a generally constructive view, with most commentary focusing on the durability of the cystic fibrosis franchise, the breadth of the pipeline and how these factors feed into valuation targets and rating changes.Uppdatering av berättelse • Dec 18
VRTX: Cystic Fibrosis And Gene Editing Advances Will Drive Upside Potential
Narrative Update The analyst price target for Vertex Pharmaceuticals has been modestly reduced to about $604 from roughly $616 as analysts factor in a slightly higher discount rate and marginally slower revenue growth, partially offset by improved profitability and a lower assumed future P/E multiple. Analyst Commentary Bullish analysts remain broadly constructive on Vertex Pharmaceuticals, emphasizing durable execution in cystic fibrosis, a deep late stage pipeline, and multiple emerging revenue drivers that, in their view, support premium valuation multiples despite modest target tweaks.Uppdatering av berättelse • Dec 04
VRTX: Kidney Pipeline And Gene Editing Will Shape Next Phase
The analyst price target for Vertex Pharmaceuticals has been nudged higher to about $485 from roughly $480 as analysts point to a healthier long term earnings profile supported by ongoing strength in the cystic fibrosis franchise, measured diversification investments, and an increasingly innovation focused large cap biopharma setup. Analyst Commentary Recent research updates on Vertex Pharmaceuticals highlight a broadly constructive stance on the name, with most price target changes and rating initiations reinforcing confidence in the company’s growth algorithm and innovation pipeline, even as some voices flag valuation and execution constraints as the franchise matures.Analysartikel • Nov 11
Vertex Pharmaceuticals' (NASDAQ:VRTX) Performance Is Even Better Than Its Earnings Suggest
Even though Vertex Pharmaceuticals Incorporated's ( NASDAQ:VRTX ) recent earnings release was robust, the market didn't...Analysartikel • Sep 19
Vertex Pharmaceuticals Incorporated's (NASDAQ:VRTX) Popularity With Investors Is Under Threat From Overpricing
It's not a stretch to say that Vertex Pharmaceuticals Incorporated's ( NASDAQ:VRTX ) price-to-sales (or "P/S") ratio of...Uppdatering av berättelse • Sep 04
Gene Editing And New Therapies Will Transform Global Healthcare
Analysts maintain a cautious-but-constructive stance on Vertex Pharmaceuticals, citing strong CF performance and resilient topline results offset by pipeline setbacks and future revenue concentration risks, with the consensus price target unchanged at $481.04. Analyst Commentary Bullish analysts highlight Vertex’s continued strong execution track record, robust base cystic fibrosis (CF) business, solid Q2 results with topline beats, and a positive long-term growth outlook beyond near-term setbacks.Ny berättelse • Apr 08
New ALYFTREK And JOURNAVX Will Expand Patient Access
Vertex is set to drive revenue growth by expanding its drug portfolio, notably with ALYFTREK and JOURNAVX, targeting new patient demographics.Seeking Alpha • Apr 06
Vertex Pharmaceuticals: A Look At Their Pain Therapy Program
Summary Vertex Pharmaceuticals is diversifying from its cystic fibrosis dominance into pain, sickle cell disease, beta thalassemia, and type 1 diabetes, with approved products in each area. Suzetrigine (Journavx) shows promise as a non-addictive pain treatment, offering systemic relief without opioid-related side effects, but faces Tier 3 insurance hurdles. Financially strong with a market cap of $124bn and $11.2bn in cash, Vertex's pain program needs further trials to overcome high placebo effects in Lumbosacral Radiculopathy. While Vertex's diversification is commendable, investors should wait for a few quarters of revenue from the pain program before making investment decisions. Read the full article on Seeking AlphaSeeking Alpha • Mar 06
Vertex Pharmaceuticals: Company Passes My Health Check With Flying Colors, Upholding Buy Rating
Summary Vertex Pharmaceuticals Incorporated's stock has shown resilience, recovering from dips and maintaining a strong long-term growth trajectory, driven by its robust CF franchise and new product approvals. The company’s 2024 performance was solid, with TRIKAFTA/KAFTRIO generating >$10bn revenues, and 2025 guidance suggesting continued growth despite some challenges. Vertex's diversification efforts include the approval of pain therapy JOURNAVX and gene therapy Casgevy, with potential multi-billion-dollar revenue contributions from these and other pipeline drugs. Despite potential headwinds, Vertex's strong cash position and promising pipeline support a “Buy” rating for VRTX stock, with expectations of further long-term growth and multiple blockbuster drugs. Read the full article on Seeking AlphaAktieägarnas avkastning
| VRTX | US Biotechs | US Marknad | |
|---|---|---|---|
| 7D | 8.4% | 4.5% | 1.0% |
| 1Y | 32.8% | 38.3% | 18.4% |
Avkastning vs industri: VRTX presterade sämre än US Biotechs branschen som gav 38.3 % under det senaste året.
Avkastning vs Marknaden: VRTX översteg US marknaden som gav 18.4 % under det senaste året.
Prisvolatilitet
| VRTX volatility | |
|---|---|
| VRTX Average Weekly Movement | 4.1% |
| Biotechs Industry Average Movement | 10.0% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.1% |
Stabil aktiekurs: VRTX har inte haft någon betydande prisvolatilitet under de senaste 3 månaderna jämfört med marknaden för US.
Volatilitet över tid: VRTX s veckovolatilitet ( 4% ) har varit stabil under det senaste året.
Om företaget
| Grundad | Anställda | VD OCH KONCERNCHEF | Webbplats |
|---|---|---|---|
| 1989 | 6,400 | Reshma Kewalramani | www.vrtx.com |
Vertex Pharmaceuticals Incorporated bedriver verksamhet som ett bioteknikföretag i USA, Europa och internationellt. Företaget erbjuder banbrytande läkemedel för personer med allvarliga sjukdomar, med fokus på specialmarknader såsom cystisk fibros (CF), sicklecellanemi (SCD), transfusionsberoende beta-talassemi (TDT) och akut smärta. Företaget marknadsför TRIKAFTA/KAFTRIO för personer med CF som har minst en F508del-mutation och som är 2 år eller äldre; ALYFTREK för behandling av personer med CF som är 6 år eller äldre; SYMDEKO/SYMKEVI för behandling av patienter med CF som är 6 år eller äldre; ORKAMBI för CF-patienter som är 1 år eller äldre; samt KALYDECO för behandling av patienter som är 1 månad eller äldre och har CF i kombination med ivacaftor.
Vertex Pharmaceuticals Incorporated Sammanfattning av grunderna
| VRTX grundläggande statistik | |
|---|---|
| Börsvärde | US$134.25b |
| Vinst(TTM) | US$4.41b |
| Intäkter(TTM) | US$12.59b |
30.2x
P/E-förhållande10.6x
P/S-förhållandeÄr VRTX övervärderat?
Se Verkligt värde och värderingsanalysResultat & intäkter
| VRTX resultaträkning (TTM) | |
|---|---|
| Intäkter | US$12.59b |
| Kostnad för intäkter | US$5.67b |
| Bruttovinst | US$6.92b |
| Övriga kostnader | US$2.51b |
| Intäkter | US$4.41b |
Senast redovisade vinst
Jun 30, 2026
Nästa vinstdatum
n/a
| Vinst per aktie (EPS) | 17.38 |
| Bruttomarginal | 54.96% |
| Nettovinstmarginal | 35.00% |
| Skuld/egenkapitalförhållande | 0% |
Hur har VRTX utvecklats på lång sikt?
Se historisk utveckling och jämförelseFöretagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/08/12 13:54 |
| Aktiekurs vid dagens slut | 2026/08/12 00:00 |
| Intäkter | 2026/06/30 |
| Årlig intjäning | 2025/12/31 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som används för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och handledningar på Youtube.
Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
Vertex Pharmaceuticals Incorporated bevakas av 59 analytiker. 16 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| Jasper Hellweg | Argus Research Company |
| Brian Skorney | Baird |
| Eliana Merle | Barclays |